universal influenza vaccine (BPL-1357) / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

BPL-1357 Against H1N1 Influenza Virus Challenge (clinicaltrials.gov) - P2 | N=126 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2024 ➔ Feb 2025

Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Temperature Stability of BPL-1357, a BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (IDWeek 2024) - No abstract available

Infectious Disease • Influenza

Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of the Safety of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (IDWeek 2024) - No abstract available

Clinical • P1 data • Infectious Disease • Influenza

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2023 ➔ Mar 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

New universal flu vaccine enters trial phase (European Scientist) - "A phase 1 clinical trial for a new flu vaccine started in the summer in the United States. This controlled trial will test the safety of the vaccine and its ability to elicit immune responses. The vaccine candidate, named BPL-1357...It has produced excellent results in laboratory tests on mice. The clinical trial will assess its impact on humans for the first time."

Trial status • Infectious Disease • Influenza